Anthony Petrone
Stock Analyst at Mizuho
(3.95)
# 570
Out of 5,163 analysts
218
Total ratings
51.88%
Success rate
9.56%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Maintains: Outperform | $72 → $85 | $79.49 | +6.93% | 8 | Feb 27, 2026 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $90 → $100 | $63.35 | +57.85% | 10 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $21 → $22 | $21.59 | +1.90% | 3 | Feb 20, 2026 | |
| DXCM DexCom | Maintains: Outperform | $78 → $90 | $64.24 | +40.10% | 4 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $130 → $85 | $58.62 | +45.00% | 8 | Feb 12, 2026 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $80 | $59.92 | +33.51% | 17 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $140 → $115 | $69.13 | +66.35% | 9 | Feb 5, 2026 | |
| EXAS Exact Sciences | Downgrades: Neutral | $85 → $105 | $103.57 | +1.38% | 2 | Jan 20, 2026 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $4.38 | +128.31% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $58.46 | +23.16% | 10 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $120 | $85.49 | +40.37% | 4 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $69.92 | +43.02% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $32.34 | +23.69% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $77.32 | +29.33% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $230.84 | +29.96% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $81.81 | +22.23% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.12 | +3.83% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $107.32 | +25.79% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $108.03 | +24.97% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $18.84 | -4.46% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $87.14 | +14.76% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $8.79 | +36.52% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $97.02 | +80.38% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.64 | +609.22% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $67.96 | -14.66% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $15.15 | -7.59% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $70.77 | +48.37% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $472.16 | -17.40% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $108.06 | -38.00% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $93.20 | +87.77% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $10.81 | +131.27% | 3 | May 13, 2020 |
Lantheus Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $72 → $85
Current: $79.49
Upside: +6.93%
Establishment Labs Holdings
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $63.35
Upside: +57.85%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $21 → $22
Current: $21.59
Upside: +1.90%
DexCom
Feb 13, 2026
Maintains: Outperform
Price Target: $78 → $90
Current: $64.24
Upside: +40.10%
Inspire Medical Systems
Feb 12, 2026
Maintains: Outperform
Price Target: $130 → $85
Current: $58.62
Upside: +45.00%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $90 → $80
Current: $59.92
Upside: +33.51%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $140 → $115
Current: $69.13
Upside: +66.35%
Exact Sciences
Jan 20, 2026
Downgrades: Neutral
Price Target: $85 → $105
Current: $103.57
Upside: +1.38%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $4.38
Upside: +128.31%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $58.46
Upside: +23.16%
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $85.49
Upside: +40.37%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $69.92
Upside: +43.02%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $32.34
Upside: +23.69%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $77.32
Upside: +29.33%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $230.84
Upside: +29.96%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $81.81
Upside: +22.23%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.12
Upside: +3.83%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $107.32
Upside: +25.79%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $108.03
Upside: +24.97%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $18.84
Upside: -4.46%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $87.14
Upside: +14.76%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $8.79
Upside: +36.52%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $97.02
Upside: +80.38%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $5.64
Upside: +609.22%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $67.96
Upside: -14.66%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $15.15
Upside: -7.59%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $70.77
Upside: +48.37%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $472.16
Upside: -17.40%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $108.06
Upside: -38.00%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $93.20
Upside: +87.77%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $10.81
Upside: +131.27%